Precision targeting—Developing small-molecule inhibitors or stabilizers to modulate AID’s activity in pathologies (e.g., inhibitors for AID-driven lymphomas, activators for HIGM2 patients with hypomorphic variants). The gene discussed is AICDA; the disease is lymphoma.